HLA-A*31:01与奥卡西平致儿童DRESS综合征
本文报告一名难治性局灶性癫痫患儿在服用奥卡西平后发生伴嗜酸性粒细胞增多和全身症状的药物反应(DRESS),事后药物基因组学检测发现HLA-A*31:01。文中还综述了抗癫痫药物超敏反应的人群流行率及相关HLA等位基因,并讨论用药前药物基因组筛查的潜在价值。
要点
- 奥卡西平可致DRESS等迟发型超敏反应,HLA-B*15:02并非其常规筛查指标。
- 本文病例事后检出HLA-A*31:01,提示其可能与奥卡西平致DRESS相关。
- 用药前药物基因组筛查在癫痫治疗中的价值尚待进一步评估。
核心结论
- 一名多种抗癫痫药物难治的局灶性癫痫患儿在奥卡西平给药后发生DRESS,事后药物基因组学检测检出HLA-A*31:01。
- 奥卡西平说明书中目前仅涉及HLA-B*15:02与特定 ancestry 人群超敏反应的信息,且不常规推荐用药前筛查该等位基因。
- 作者提出用药前药物基因组筛查或有助于评估癫痫患者发生超敏反应的风险。
研究设计与样本
- 本文为个案报告,并附文献综述与药物基因组学分析。
- 病例对象为一名局灶性癫痫、对多种抗癫痫药物难治的儿科患者。
- HLA等位基因检测在发生DRESS后回顾性(post hoc)进行,并评估了抗癫痫药物间的结构相似性及其与HLA抗原蛋白的分子关联。
主要发现
- 该患儿在奥卡西平给药后出现伴嗜酸性粒细胞增多和全身症状的药物反应(DRESS)。
- 事后药物基因组学检测发现HLA-A*31:01。
- 文中综述了抗癫痫药物超敏反应的人群流行率及相关HLA等位基因。
关键数值与推荐
- 奥卡西平获FDA批准的说明书目前载有HLA-B*15:02与该等位基因高发人群超敏反应相关的药物基因组学信息。
- 与卡马西平不同,奥卡西平给药前不常规推荐筛查HLA-B*15:02。
- 即使使用卡马西平,临床上也并非总在开始治疗前进行HLA抗原检测,原因包括医生对推荐缺乏了解和希望不延误治疗。
临床怎么用
- 对使用奥卡西平后出现皮疹伴全身症状的癫痫患儿,应考虑DRESS等迟发型超敏反应。
- 现有资料尚不足以支持奥卡西平用药前常规筛查HLA-B*15:02。
- 用药前药物基因组筛查用于评估抗癫痫药物超敏风险的价值仍需进一步研究。
局限性
- 本文为单个病例报告,不能确立HLA-A*31:01与奥卡西平致DRESS的因果关系。
- 药物基因组学检测为事后进行,未提供用药前筛查的前瞻性证据。
- 文中未报告该病例的具体年龄、剂量、潜伏期及人群流行率的具体数值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Oxcarbazepine is an antiepileptic drug (AED) commonly used as a first-line treatment option for focal epilepsy. Several AEDs, including carbamazepine, oxcarbazepine, and phenytoin are associated with various delayed-hypersensitivity reactions such as drug reaction with eosinophilia and systemic symptoms, Stevens-Johnson syndrome, or toxic epidermal necrolysis. The Food and Drug Administration-approved label for oxcarbazepine currently presents information regarding a pharmacogenomic association with the HLA antigen allele HLA-B*15:02 and hypersensitivity reactions in certain ancestry groups with a high incidence of this allele. However, unlike carbamazepine, screening for the presence of this allele is not routinely recommended before administration of oxcarbazepine. In practice, even with carbamazepine, HLA antigen testing is not always performed before initiating treatment because of lack of physician awareness of the recommendations and because of the desire to initiate treatment without delay. We present the clinical course of a pediatric patient with focal epilepsy refractory to several AEDs who developed drug reaction with eosinophilia and systemic symptoms after oxcarbazepine administration. The pharmacogenomic testing for various HLA antigen alleles was performed post hoc, and results were evaluated for structural similarities between AEDs and their molecular associations with HLA antigen proteins. In addition, we review the population-wide prevalence of various hypersensitivity reactions to AEDs and associated HLA antigen alleles. Finally, we discuss the potential utility of preemptive pharmacogenomic screening of patients before pharmacological treatment of epilepsy to assess the risk of developing hypersensitivity reactions.
引用
- Kim H, Chadwick L, Alzaidi Y, et al. HLA-A*31:01 and Oxcarbazepine-Induced DRESS in a Patient With Seizures and Complete DCX Deletion. Pediatrics. 2018. PMID: 29610167. doi:10.1542/peds.2017-1361
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。